Helicobacter pylori: Prevalence of antimicrobial resistance in clinical isolates

British Journal of Biomedical Science

Volumn 63, Issue 3, 2006, Pages 113-116

  Hooton, Carmel ^a   Dempsey, C ^b   Keohane, J ^a   O'Mahony, S ^a   Crosbie, O ^a   Lucey, B ^a  

^a Department of Medicine National University of Ireland Cork   (Ireland)

^b Department of Chemistry   (Ireland)

Author keywords

Drug resistance, microbial; Helicobacter pylori

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; METRONIDAZOLE; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM CULTURE; BACTERIUM ISOLATE; CONTROLLED STUDY; DNA SEQUENCE; DRUG EFFICACY; GENE MUTATION; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HISTOPATHOLOGIC SKIN REACTION; HUMAN; IN VITRO STUDY; IRELAND; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; STOMACH BIOPSY;

HELICOBACTER PYLORI;

EID: 33750370311     PISSN: 09674845     EISSN: None     Source Type: Journal    
DOI: 10.1080/09674845.2006.11732730     Document Type: Article

References (32)

1. Calam J. Clinical science of Helicobacter pylori infection: ulcers and NSAIDs. Br Med Bull 1998; 54: 55-62.
2. Rosenstock S, Kay L, Rosenstock C, Anderson L, Bonnevie O. Relationship between Helicobacter pylori infection and gastrointestinal symptoms and syndromes. Gut 1997; 41 (2): 169-76.
3. Megraud F, Lamouliatte H. Review article: the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther 2003; 17: 1333-43.
4. Malfertheiner P, Megraud F, O'Morain C et al. and the European Helicobacter pylori Study Group (EHPSG). Current concepts in the management of Helicobacter pylori infection - the Maastrict 2-2000 Consensus Report. Aliment Pharmacol Ther 2002; 16: 167-8.
5. Lam SK, Talley NJ. Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection. J Gastroenterol Hepatol 1998; 13: 1-12.
6. Hunt RH, Fallone C, Veldhuyzen van Zaten S, Sherman P, Smaill F, Thompson A. Risks and benefits of Helicobacter pylori eradication: current status. Can J Gastroenterol 2002; 16: 57-62.
7. Gisbert JP Gonzalez L, Calvet X, et al. Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: a meta-analysis of eradication of Helicobacter pylori. Aliment Pharmacol Ther 2000; 14: 1319-28.
8. O'Morain C, Montague S. Challenges to therapy in the future. Helicobacter 2000; 5: 23-6.
9. Gasbarrini A, Ojetti V, Armuzzi A et al. Efficacy of a multistep strategy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2000; 14: 179-83.
10. Fonta C, Favaro M, Minelli S, Criscuolo A, Pietroiusti A, Galante A. New site of modification of 23S rRNA associated with clarithromycin resistance of Helicobacter pylori clinical isolates. Antimicrob Agents Chemother 2002; 46: 3765-9.
11. Russmann H, Volkhard A, Kempf J, Koletzko S, Heesemann J, Autenrieth I. Comparison of fluorescence in situ hybridisation and conventional culturing for detection of Helicobacter pylori in gastric biopsy specimens. J Clin Microbiol 2001; 39: 304-8.
12. Fontana C, Favaro M, Pietroiusti A, Pistoia E, Galante A, Favalli C. Detection of clarithromycin-resistant Helicobacter pylori in stool samples. J Clin Microbiol 2003; 41: 3636-40.
13. Veldhuyzen Van Zanten S, Mcahado S, Lee J. One-week triple therapy with esomeprazole, clarithromycin, and metronidazole provides effective eradication of H. pylori infection. Aliment Pharmacol Ther 2003; 17: 1381-7.
14. Megraud F, Lehn N, Lind T, Bayerdorffer EO, Morain C, Spiller R. Antimicrobial susceptibility testing of Helicobacter pylori in a large multicenter trial: the MACH 2 study. Antimicrob Agents Chemother 1999; 43: 2747-52.
15. Glupczynski Y. Culture of Helicobacter pylori from gastric biopsies and antimicrobial susceptibility testing. In: Lee A, Megraud F, eds. Helicobacter pylori: techniques for clinical diagnosis and basic research. London: WB Saunders, 1996: 17-32.
16. Glupezynski Y, Andersen L, Lopez-Bera M, Megraud F. Towards standardisation of antimicrobial susceptibility testing of Helicobacter pylori: preliminary results by a European multicentre study group. Gut 1998; 43 (Suppl 2): A47.
17. Glupczynski Y, Megraud F, Andersen LP, Lopez-Bera M. Antibiotic susceptibility of Helicobacter pylori in Europe in 1998: results of a third multicentre study. Gut 1999: 45 (Suppl 111): A105.
18. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing, 1999: VIth informational supplement. MI00S9 19,1. National Committee for Clinical Laboratory Standards, Villanova.
19. Dong H. Isolation and characterization of tetracycline resistant Helicobacter pylori. Antimicrob Agents Chemother 2000; 44: 3203-5.
20. Altschul S, Madden T, Schaffer A, Zhang J, Zhang Z, Miller W Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 1997; 25: 3389-402.
21. Tytgat G. Helicobacter pylori - reflections for the next millennium. Gut 1999; 45 (Suppl 1): 145-7.
22. Blaser M. Hypothesis: the changing relationships of Helicobacter pylori and humans: implications for health and disease. J Infect Dis 1999; 179: 1523-30.
23. Dore M, Leandro G, Realdi G, Sepulveda A, Graham D. Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy: a meta-analytical approach. Dig Dis Sci 2000; 45: 68-76.
24. Houben M, Van De Beek D, Hensen E, Craen A, Rauws E, Tytgat G. A systematic review of Helicobacter pylori eradication therapy - the impact of antimicrobial resistance on eradication rates. Aliment Pharmacol Ther 1999; 13: 1047-55.
25. Toracchio S, Cellini L, Di Campli E et al. Role of antimicrobial susceptibility testing on efficacy of triple therapy in Helicobacter pylori eradication. Aliment Pharmacol Ther 2000; 14: 1639-41.
26. Romano M, Iovene M, Montella F et al. Pretreatment antimicrobial susceptibility testing in the eradication of H. pylori infection. Am J Gastroenterol 2000; 95: 3317-8.
27. Jenks P. Causes of failure of eradication of Helicobacter pylori: antibiotic resistance is the major cause, and susceptibility testing may help. BMJ 2002; 325: 3-4.
28. De Boer W, Tytgat G. Treatment of Helicobacter pylori infection. BMJ 2000; 320: 31-4.
29. Buckley M, Xia H, Hyde D, Keane C, O'Morain C. Metronidazole resistance reduces efficacy of triple therapy and leads to secondary clarithromycin resistance. Dig Dis Sci 1997; 42: 2111-5.
30. Xia H, Buckley M, Keane M, O'Morain C. Clarithromycin resistance in Helicobacter pylori: prevalence in untreated dyspeptic patients and stability in vitro. J Antimicrob Chemother 1996; 37: 473-81.
31. Taylor N, Fox J, Akopyants N et al. Long-term colonisation with single and multiple strains of Helicobacter pylori assessed by DNA fingerprinting. J Clin Microbiol 1995; 33: 918-23.
32. Bina J, Alm R, Uria-Nickelsen M, Thomas S, Trust T, Hancock R. Helicobacter pylori uptake and reflux: basis for intrinsic susceptibility to antibiotics in vitro. Antimicrob Agents Chemother 2000; 44: 248-54.